Personalised medicine groups patients using biological and clinical information relevant to treatment. a biomarker is shaped by patients, clinicians, hospitals and the prevention systems that determine when a problem is detected and treated.
Reading confidence0% of the way to explored
The deeper explanation
The answer in detail
A biomarker is a measurable sign linked to a disease or treatment response, such as a molecule, image or genetic variant. It becomes useful only after careful validation.
Why it matters
Treatment matched to the patient can reduce trial and error, while raising important questions about data, evidence and fair access.
The public system around a biomarker
Pharmaceutical incentives, diagnostic capacity and household income affect who receives effective care and how quickly evidence becomes practice.
The consequences reach public budgets and workplaces: prevention can reduce later costs, while unequal access shifts illness and lost work onto families and communities.
System lens
What makes this more complicated?
Three layers that help explain what changes the outcome.
Starting conditions
History, resources and institutional capacity set the starting position before the visible outcome appears.
Limits and trade-offs
Rules, capacity and competing priorities limit which responses are practical, even when several options look possible.
Choices and distribution
The outcome depends on who can change those conditions and how its consequences are shared.
Could personalised medicine replace standard treatments?
Shared background, people, references and other questions for this story collection.
Read the main storyMeet the players
The people and organisations that can change what happens in “Could personalised medicine replace standard treatments?”. Each card explains a goal, a source of leverage and a constraint.
Government
Public-health authorities
Officials organising prevention and care
Wants toreduce harm with available capacity
LeverageRules, funding, surveillance and service design.
Read profile: Public-health authorities
Health authorities decide how prevention, diagnosis, treatment and staffing respond to the issue in this story. Their choices determine who gets care and how quickly.
Budgets, workforce shortages, evidence and public trust limit what they can deliver.
What to watchWatch the decisions, resources or constraints that can materially change this actor’s position.
Sources: [1]
Scientific community
Clinicians and researchers
People producing and applying medical evidence
Wants toidentify what works and what remains uncertain
LeverageEvidence, diagnosis and professional practice.
Read profile: Clinicians and researchers
Clinicians and researchers turn observations into tests, treatments or guidance. Their evidence changes what authorities and patients understand about the question.
Small studies, incomplete data and the time needed for safe testing limit how quickly they can settle it.
What to watchWatch the decisions, resources or constraints that can materially change this actor’s position.
Sources: [1]
Companies
Pharmaceutical and medical suppliers
Companies producing medicines, tests or equipment
Wants todevelop and supply usable products
LeverageManufacturing capacity, patents and distribution.
Read profile: Pharmaceutical and medical suppliers
Suppliers decide which medicines, tests, devices or vaccines to develop and how much to produce. Their choices affect availability and price.
They depend on regulation, patents, raw materials, skilled workers and purchasing commitments.
What to watchWatch the decisions, resources or constraints that can materially change this actor’s position.
Sources: [1]
Service providers
Hospitals and care services
Organisations delivering treatment
Wants tokeep care available when demand changes
LeverageAccess to frontline care and real-world data.
Read profile: Hospitals and care services
Hospitals and local services turn policy and evidence into appointments, treatment and follow-up. Their staffing and equipment determine whether an intervention works in practice.
Space, budgets, waiting lists and exhausted workers constrain them.
What to watchWatch the decisions, resources or constraints that can materially change this actor’s position.
Sources: [1]
Community
Patients and families
People who experience the outcome directly
Wants toreceive effective and affordable care
LeverageLived experience, demand and public pressure.
Read profile: Patients and families
Patients and families experience the issue through symptoms, waiting times, costs, work and daily life. Their behaviour also affects prevention and demand.
They have limited control over prices, clinical capacity and the quality of information available.
What to watchWatch the decisions, resources or constraints that can materially change this actor’s position.
Sources: [1]
Decisions travel between them
Public-health authoritiesClinicians and researchersPublic-health authorities and Clinicians and researchers shape the outcome through the decisions and limits described in this story.
Public-health authoritiesPharmaceutical and medical suppliersPublic-health authorities and Pharmaceutical and medical suppliers shape the outcome through the decisions and limits described in this story.
Public-health authoritiesHospitals and care servicesPublic-health authorities and Hospitals and care services shape the outcome through the decisions and limits described in this story.
Public-health authoritiesPatients and familiesPublic-health authorities and Patients and families shape the outcome through the decisions and limits described in this story.
Sources & visual credits
Flags and logos identify the actors; they do not imply endorsement.
Story collection
6 questions to explore
Open a question to read its explainer and follow the linked questions in this collection.
- 01Could personalised medicine replace standard treatments?Featured
- 02How can a genetic test change a treatment decision?
- 03You are hereOpen now
- 04Why can the same medicine work differently for different people?
- 05Who should control genomic health data?
- 06Could personalised medicine widen health inequality?
A quick glossary for this collection.
Precision medicineCare tailored using relevant biological and clinical differences.
GenomeThe complete set of an organism’s genetic material.
BiomarkerA measurable indicator of disease or biological response.
PharmacogenomicsThe study of how genes influence response to medicines.
Targeted therapyTreatment aimed at a specific molecular feature.
Risk factorA characteristic or exposure associated with a higher chance of an outcome.
Sources for the whole story
How we work ↗Sources to start with
These references support the story collection as a whole.
Take the question with you
Visit the shop →Make complex ideas conversation starters.
Explore humorous products inspired by stories such as Could personalised medicine replace standard treatments?.